Chronic obstructive pulmonary disease: current burden and future projections

Lopez, Alan D; Shibuya, Kenji; Rao, Chalapati; Mathers, Colin; Hansell, Anna; Held, Leonhard; Schmid, Volker; Buist, Sonia

doi:10.1183/09031936.06.00025805

Cited by 1,147 publications

(832 citation statements)

References 58 publications

Supporting

Mentioning

748

Contrasting

Unclassified

Order By: Relevance

“…The world bank estimated that COPD and asthma were responsible for 2.2% of the global burden of disease in East Mediterranean countries in 1999[1]. Worldwide, COPD is expected to move up from the 12th leading cause of DALYs in 1990 to the 5th leading cause in 2020[1,16]. …”

Section: Global Mortality Dalys and Economic Costs Of Copd In Menamentioning

confidence: 99%

Burden of Chronic Respiratory Diseases (CRD) in Middle East and North Africa (MENA)

Abdallah¹,

Taktak²,

Chtourou³

et al. 2011

World Allergy Organization Journal

View full text Add to dashboard Cite

Chronic respiratory diseases involve a heterogenous group of diseases, including, chronic obstructive pulmonary disease (COPD), asthma, sleep apnea syndrome, pulmonary hypertension, and many occupational diseases. They affect more than one billion people worldwide. Their medical, social, and economic impacts are heavy, especially in developing countries such as Middle East and North Africa countries, where they represent a public health problem. They are essentially represented by COPD, asthma, and allergic diseases. Chronic respiratory diseases are increasing in frequency, morbidity, and mortality. In addition, their economic and social impact is increasing rapidly in this region. Main risk factors are represented by tobacco smoking and exposure to biomass fuel. Smoking prevention and standardized management programs for asthma and COPD are now available but prompt actions are needed to make them more effective in this region and thus avoid an adverse impact on national economic development.

show abstract

Section: Global Mortality Dalys and Economic Costs Of Copd In Menamentioning

confidence: 99%

Burden of Chronic Respiratory Diseases (CRD) in Middle East and North Africa (MENA)

Abdallah¹,

Taktak²,

Chtourou³

et al. 2011

World Allergy Organization Journal

View full text Add to dashboard Cite

show abstract

“…Despite all efforts from the scientific community and health care providers, mortality and morbidity from chronic obstructive pulmonary disease (COPD) and similar diseases constantly grows (Lopez et al 2006). COPD, a major Ieva Bruzauskaite and Jovile Raudoniute have contributed equally to this work.…”

Section: Introductionmentioning

confidence: 99%

Native matrix-based human lung alveolar tissue model in vitro: studies of the reparatory actions of mesenchymal stem cells

et al. 2016

View full text Add to dashboard Cite

Studies of lung diseases in vitro often rely on flat, plastic-based monocultures, due to short lifespan of primary cells, complicated anatomy, lack of explants, etc. We hereby present a native 3D model with cues for repopulating epithelial cells. Abilities of mesenchymal stem cells (MSC) to modulate bacterial lipopolysaccharide (LPS) and cigarette smoke-induced injury to pulmonary epithelium were tested in our model. Post-mortem human lung tissue was sliced, cut and decellularized. Resulting matrix pads were reseeded with pulmonary epithelium (A549 line). Markers of the layer integrity and certain secreted proteins in the presence of cigarette smoke extract (CSE) and LPS were assessed via Western blot, ELISA and RT-PCR assays. In parallel, the effects of MSC paracrine factors on exposed epithelial cells were also investigated at gene and protein levels. When cultured on native 3D matrix, A549 cells obtain dual, type I-and II-like morphology. Exposure to CSE and LPS leads to downregulation of several epithelial proteins and suppressed proliferation rate. MSC medium added to the model restores proliferation rate and some of the epithelial proteins, i.e. e-cadherin and beta-catenin. CSE also increases secretion of proinflammatory cytokines by epithelial cells and upregulates transcription factor NFjB. Some of these effects might be counteracted by MSC in our model. We introduce repopulated decellularized lung matrix that highly resembles in vivo situation and is convenient for studies of disease pathogenesis, cytotoxicology and for exploring therapeutic strategies in the human lung context in vitro. MSC paracrine products have produced protecting effects in our model.

show abstract

“…COPD is highly prevalent [2], responsible for 2.7 million deaths globally in 2000 [3], and associated with increased morbidity and mortality as well as a reduced quality of life [4,5]. The 1997…”

Section: Introductionmentioning

confidence: 99%

Aclidinium bromide provides long-acting bronchodilation in patients with COPD

Chanez¹,

Burge²,

Dahl³

et al. 2010

Pulmonary Pharmacology & Therapeutics

View full text Add to dashboard Cite

Aclidinium bromide is a novel, long-acting, muscarinic antagonist in phase III development for the maintenance treatment of COPD. This phase IIb study investigated the efficacy and safety of aclidinium for the treatment of moderate to severe COPD to establish the optimal dose for phase III studies. A total of 464 patients with moderate to severe stable COPD were randomised to double-blind, once-daily treatment with aclidinium (25, 50, 100, 200, or 400 μg), placebo, or openlabel tiotropium (18 μg) for 4 weeks. Spirometric measurements were performed at 22-24 h after the first dose and then at weekly intervals, and from 0.5-6 h post-dose on day 1 and day 29. Compared with placebo, aclidinium 200 μg and 400 μg significantly increased trough FEV 1 on day 29 versus baseline. During the first 6 h post-dose, the bronchodilatory effect of aclidinium (all doses) on day 1 was comparable to that on day 29. Time to peak FEV 1 was 3 h for aclidinium 100-400 μg. Aclidinium was well tolerated, with no dose-dependent effect on ECG, laboratory parameters, or adverse events. The incidence of AEs was generally comparable to placebo. Aclidinium produced sustained bronchodilation over 24 h and was well tolerated during this short-term study. Based on these data, aclidinium 200 μg was selected as the investigational dose for future clinical trials in COPD.

show abstract

Chronic obstructive pulmonary disease: current burden and future projections

Cited by 1,147 publications

References 58 publications

Burden of Chronic Respiratory Diseases (CRD) in Middle East and North Africa (MENA)

Burden of Chronic Respiratory Diseases (CRD) in Middle East and North Africa (MENA)

Native matrix-based human lung alveolar tissue model in vitro: studies of the reparatory actions of mesenchymal stem cells

Aclidinium bromide provides long-acting bronchodilation in patients with COPD

Contact Info

Product

Resources

About